Your source for biopharma news and jobs
Joined February 2009
- Tweets 37,595
- Following 2,934
- Followers 25,798
- Likes 4,657
7,068 Photos and videos
Officials sanctioned Dabur India months after FDA inspectors found bird droppings and data integrity deficiencies during an inspection of the plant.
hubs.li/Q04lcrcK0
1
227
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.
hubs.li/Q04lc1wb0
1
2
335
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
hubs.li/Q04lbH_y0
2
3
607
Novo Nordisk said that the information affected by the breach shouldn’t allow third parties to “identify participants in our clinical trials” despite “unauthorized access” to patients’ personal data.
hubs.li/Q04lbPJK0
2
1
235
Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.
hubs.li/Q04lbTgd0
1
1
267
The staffing changes will focus resources on work that creates the highest impact for patients, according to @genentech. The number of employees affected is unknown, but longtime veteran Vishva Dixit is out.
#layoffs #biopharma #biospace
hubs.li/Q04l3yw20
1
3
3
563
Just 23% of respondents to a BioSpace LinkedIn poll expect the biopharma job market will rebound in 2026. Three experts discuss when they see a turnaround happening and what's impacting hiring practices.
#jobmarket #biopharma #biospace
hubs.li/Q04l2Z9t0
1
2
2
232
For the second time in 2026, the number of biopharma professionals affected by made or projected workforce reductions rose year over year.
#layoffs #biopharma #biospace
hubs.li/Q04l2Rtm0
1
2
272
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
hubs.li/Q04l27M50
3
241
Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
hubs.li/Q04l1Sq70
4
331
Instead of using viral vectors, SonoThera’s genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.
hubs.li/Q04l1G7r0
1
6
385
In this episode of Denatured, you’ll be hearing from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc as they discuss the rise of Southern Europe’s biotech ecosystem.
hubs.li/Q04l10ph0
2
263
The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.
hubs.li/Q04kKV6p0
2
1,918
The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.
hubs.li/Q04kQvWZ0
14
15,123
Parabilis Medicines is joining the parade of biotechs going public, with one key difference—more money.
hubs.li/Q04kLvLd0
3
508
The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.
hubs.li/Q04kPXQh0
1
257
As the industry faces policy changes and significant cuts to federal funding, local ecosystems can bolster companies through innovative resources to sustain growth and keep the U.S. at the center of biomedical innovation.
hubs.li/Q04kLNQW0
1
223
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.
hubs.li/Q04kKwlN0
1
260
Join Certara for an upcoming webinar to explore how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework.
Register: hubs.li/Q04g9gmM0
1
2
519
Improved survival on display at ASCO in Chicago; Pfizer’s unusual pact with China’s Innovent; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting.
hubs.li/Q04kQM310
2
268